BRD2 and cancer: Slow acetylators are also more prone to developing certain cancers.19 As a result, NAT modulation via small molecules and miRNAs has become a target of drug and biomarker development.20, 21 Considered together, understanding the rifampin‐induced changes in NAT expression and associated miRNAs may be of therapeutic and diagnostic value.